Skip to main content

COVID Response Best Practices

Thank you

This live web event has ended. Thank you for attending.


  • Debbie Bowers, M.BA., B.S., Sr. VP, Commercial Development, BioDot, Inc.

    26 years in supporting global Life Science customers through automation consultation, applications development and first-in-class customer care. An industrial engineer; an MBA with an emphasis in Global Marketing; and certification in Contract Law. Holistic diversity with all scientific application areas with knowledge of global best practices used in laboratories around the world. Debbie joined BioDot in 2020. Debbie acquired in-depth knowledge in all areas of liquid handling automation, detection, automated sample storage and retrieval systems and the consumables and modules required to automate complete workflows for life science applications. Prior to BioDot, Debbie had global leadership roles in sales, marketing and customer support at Hamilton Robotics, Invetech, Tecan, Corning and Baker Hughes.

  • Nigel Skinner, Ph.D., Head of Marketing, Andrew Alliance

    Commercially focused Marketing leader and results driven change agent, with 25 years experience in the life sciences, publishing and information services industries. Proven, international track record in creating and leading results oriented B2B and B2C marketing strategies. Solid business, life science and engineering education from top tier universities.

Scaling Beyond COVID Rapid Testing by BioDot
COVID is still a testing challenge for citizens, businesses, and entire countries. The pandemic afforded us (the healthcare community) the opportunity to improve processes, and most importantly to advance science. The regulatory process has streamlined approvals for testing, both in the tests used and in the labs that can perform the tests, but due the magnitude of testing, simplification and economics in testing became key drivers, and this is where rapid test technology shines. Point-of-Care (POC) Over the Counter (OTC) tests are now approved for COVID and there will be more to follow, likely in other infectious disease areas. Beyond COVID, we see a medicine cabinet filled will home tests for Influenza, Streptococcus, Pneumonia, all connected via mobile devices to your physician via telemedicine. If results are negative, only then do you proceed to Urgent Care. The applications reach far beyond infectious disease - think about food allergies. How many of us have nut, dairy, gluten or seafood allergies? When venturing out to a restaurant and verifying with the server that the food is allergy-free, would we not want to have our own portable rapid test in hand to confirm that it actually is a gluten-free dish before we indulge? The point here is COVID was the door opener to simplified, affordable testing which puts the testing device in the hands of the patient and consumer. The next step is to consider how to develop these rapid tests and how these tests can be produced at scale. That is where BioDot comes in. BioDot made its mark in this industry in 1994 with patented, non-contact, nanoliter (nL) dispensing technology and then designed instrumentation to precisely dispense volumes onto a variety of surfaces. A rapid test is typically either a lateral flow test or a biochip/biosensor device. The surfaces used in lateral flow are porous and dispensing is best done without touching (disrupting) the material (non-contact). Conversely, in biochip/biosensor applications, the surfaces are often rigid plastic wells, but they require absolute placement of many different low-volumes of liquids (>36 different types) to be dispensed simultaneously and quickly. Both examples stated (lateral flow and biochip/biosensor) benefit from BioDot’s non-contact, nanoliter dispensing technology. As with most science, development of a rapid test begins with research, progresses to prototyping, and ultimately advances to production volumes once a test has been proven and is ready for sale. BioDot has a product offering to suit the needs of our customers with entry-level R&D platforms that scale as their development and production needs get defined. Our R&D systems are used to produce batches of up to 500,000 rapid tests per year. As our customer’s tests gain market adoption, with volumes greater than 1M tests per year, migrating to our high production instrumentation for printing and lamination is common. If your group has ELISA/antigen/antibody expertise and are considering a rapid test development effort, this webinar will further expand on the trends in this space and make recommendations of how to avoid pitfalls in your “rapid test” quest.
May 6, 2021
Thu 12:00 PM EDT

Duration 1H 0M

This live web event has ended.